New ISHLT Guidelines Support Use of CareDx's HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients

Author's Avatar
Dec 22, 2022

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication1 of new guidelines by the International Society for Heart and Lung Transplantation (ISHLT) supporting the use of CareDx’s non-invasive molecular surveillance portfolio.